Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Increasingly, women with stage 2 and 3 breast cancers receive neoadjuvant therapy, after which many are eligible for breast-conserving surgery (BCS). The question often arises as to whether BCS, if achievable, provides adequate local control. We report the results of local recurrence (LR) from the I-SPY 1 Trial in the setting of maximal multidisciplinary treatment where approximately 50 % of patients were treated with BCS

Couverture du Time magazine, « The Angelina Effect » (27 mai 2013)

Couverture du Time magazine, « The Angelina Effect » (27 mai 2013) © Time magazine Entretien avec Sindy Monnier, réalisé le 26 février 2014 par Mathilde Bourrier M. B. : Que vous évoque et vous a évoqué cette couverture du Time ? S. M. : Je n’aime pas les mots employés [« The Angelina Effect »]. Le titre de la couverture du Time évoque un effet bénéfique de l’annonce publique par Angelina Jolie de sa double mastectomie prophylactique. Mais l’annonce d’Angelina Jolie a eu aussi un effet pas f..

La vaccination anti-HPV contre le cancer du col utérin

SCOPUS: re.jinfo:eu-repo/semantics/publishe

Isolated tumor cells in sentinel lymph nodes of invasive breast cancer: cell displacement or metastasis?

The goal of this study was to determine whether the presence of isolated tumoral cells (ITCs) in sentinel lymph nodes (SLNs) after core needle biopsy (CNB) is related to the time interval between CNB and surgery and to histopathologic features of invasive breast cancer. Data from 633 consecutive patients with no micrometastasis or metastasis on both frozen sections and definitive pathologic examination of SLNs were retrieved from a prospective data base. No association was found between ITCs and the time interval between CNB and SLNB. The association was significant with tumor size, the tumor lymphovascular invasion (LVI) and the histologic type of the tumor. This study adds supplementary data to the association between tumoral LVI and ITCs in SLNs, The time interval between CNB procedure and SLNB was not related to affect presence of ITCs, which might not suggest the iatrogenic origin of these cells

Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging

To evaluate the performance of 18F-fluorodeoxyglucose (FDG) positron emission tomography magnetic resonance imaging (PET/MR) for preoperative breast cancer staging

Ni malades, ni en bonne santé

Les pratiques médicales s'élargissent continuellement autour de la définition de nouveaux risques : la définition de nouvelles maladies, le dépistage génétique, l'identification de comportements néfastes, la découverte de nouveaux risques dans l'environnement viennent placer les individus à l’intersection de la santé et de la maladie. Plus les recherches cliniques et épidémiologiques sont poussées et plus elles révèlent aux individus des failles potentielles dans leur état de santé. En outre, les scanners, IRM, et autres examens plus ou moins invasifs révèlent que le corps n’est pas entièrement parfait. Les médecins et chercheurs confrontés à ces résultats doivent communiquer autour de ces nouveaux risques, sans que ne soient toujours posées les limites de ces révélations, ni leurs conséquences en termes de santé pour les individus et les populations. Ce numéro spécial se propose d’analyser les conséquences de cette prolifération des risques qui obscurcissent, décalent, brouillent les frontières entre la santé et la maladie. On s’intéressera également à l’émergence de nouvelles pratiques, oscillant entre une « médecine sur mesure » susceptible de soigner les individus dans leur singularité et des dispositifs de surveillance soulignant les contradictions entre normes préventives et attentes sociales

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

BACKGROUND: Increasingly, women with stage 2 and 3 breast cancers receive neoadjuvant therapy, after which many are eligible for breast-conserving surgery (BCS). The question often arises as to whether BCS, if achievable, provides adequate local control. We report the results of local recurrence (LR) from the I-SPY 1 Trial in the setting of maximal multidisciplinary treatment where approximately 50 % of patients were treated with BCS. METHODS: We analyzed data from the I-SPY 1 Trial. Women with tumors ≥3 cm from nine clinical breast centers received neoadjuvant doxorubicin, cyclophosphamide and paclitaxel followed by definitive surgical therapy, and radiation at physician discretion. LR following mastectomy and BCS were analyzed in relation to clinical characteristics and response to therapy as measured by residual cancer burden. RESULTS: Of the 237 patients enrolled in the I-SPY 1 Trial, 206 were available for analysis. Median tumor size was 6.0 cm, and median follow-up was 3.9 years. Fourteen patients (7 %) had LR and 45 (22 %) had distant recurrence (DR). Of the 14 patients with LR, nine had synchronous DR; one had DR > 2 years later. Only four (2 % of evaluable patients) had LR alone. The rate of LR was low after mastectomy and after BCS, even in the setting of significant residual disease. CONCLUSIONS: Overall, these patients at high risk for early recurrence, treated with maximal multidisciplinary treatment, had low LR. Recurrence was associated with aggressive biological features such as more advanced stage at presentation, where LR occurs most frequently in the setting of DR